Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
Top Page
Jubilant Pharmova Limited
(JUBLPHARMA)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹932.00
▼(-11.75% Downside)
Action:ReiteratedDate:11/01/25
Jubilant Pharmova Limited's stock score is primarily influenced by solid financial performance, with notable revenue growth and operational efficiencies. However, cash flow challenges and a high P/E ratio weigh down the score. Technical indicators suggest a neutral to slightly bullish trend, but valuation concerns limit the overall attractiveness of the stock.
Positive Factors
Diversified life-sciences portfolio
Jubilant’s multi-segment model (CDMO, radiopharma, allergy, generics) provides durable revenue diversification. CDMO can deliver long-term supply contracts, while radiopharma and allergy are higher-value niches, reducing single-market dependency and improving resilience over months.
Negative Factors
Negative free cash flow from capex
Despite solid operating cash generation, high capital spending has produced negative free cash flow. Over a 2–6 month horizon, persistent negative FCF can constrain internal funding for growth, raise refinancing needs, and limit ability to reduce leverage or return cash to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified life-sciences portfolio
Jubilant’s multi-segment model (CDMO, radiopharma, allergy, generics) provides durable revenue diversification. CDMO can deliver long-term supply contracts, while radiopharma and allergy are higher-value niches, reducing single-market dependency and improving resilience over months.
Read all positive factors
Jubilant Pharmova Limited (JUBLPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹139.80B
Dividend Yield0.46%
Average Volume (3M)7.42K
Price to Earnings (P/E)76.0
Beta (1Y)1.06
Revenue Growth10.09%
EPS Growth-19.40%
CountryIN
Employees5,399
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)5.00
Shares Outstanding159,281,140
10 Day Avg. Volume4,911
30 Day Avg. Volume7,424
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)2.01
P/FCF Ratio-334.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,310.00Price Target Upside24.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)45.5
Revenue Forecast (FY)₹91.10B
Jubilant Pharmova Limited Business Overview & Revenue Model
Company Description
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages i...
How the Company Makes Money
Jubilant Pharmova makes money through a portfolio of life-sciences revenue streams: (1) CDMO/services revenue: It earns fees and manufacturing margins by providing contract research, development, and manufacturing services for pharmaceutical custo...
Jubilant Pharmova Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 76.18B | 72.34B | 67.03B | 62.82B | 61.30B | 60.99B |
| Gross Profit | 42.43B | 46.99B | 43.52B | 42.00B | 46.42B | 45.63B |
| EBITDA | 12.02B | 10.48B | 7.93B | 6.46B | 10.66B | 14.68B |
| Net Income | 4.78B | 8.39B | 771.00M | -610.00M | 4.14B | 8.36B |
Balance Sheet | ||||||
| Total Assets | 135.21B | 127.56B | 115.48B | 111.57B | 99.91B | 89.18B |
| Cash, Cash Equivalents and Short-Term Investments | 6.23B | 10.89B | 9.56B | 10.15B | 9.86B | 6.89B |
| Total Debt | 28.83B | 27.31B | 36.64B | 36.77B | 31.92B | 28.30B |
| Total Liabilities | 69.50B | 65.18B | 61.27B | 57.65B | 46.74B | 41.77B |
| Stockholders Equity | 65.92B | 62.55B | 54.34B | 53.99B | 53.19B | 47.41B |
Cash Flow | ||||||
| Free Cash Flow | -3.71B | -435.00M | 736.00M | -1.54B | 2.38B | 12.57B |
| Operating Cash Flow | 3.69B | 10.72B | 9.71B | 6.61B | 8.38B | 17.84B |
| Investing Cash Flow | -6.31B | 4.88B | -6.08B | -5.44B | -3.80B | -7.39B |
| Financing Cash Flow | -1.84B | -14.53B | -4.33B | -1.57B | -325.99M | -17.09B |
Jubilant Pharmova Limited Technical Analysis
Neutral
1056.10
Price Trends
884.06
Negative
978.58
Negative
1050.64
Negative
Market Momentum
-6.81
Negative
55.16
Neutral
73.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLPHARMA, the sentiment is Neutral. The current price of 1056.1 is above the 20-day moving average (MA) of 839.32, above the 50-day MA of 884.06, and above the 200-day MA of 1050.64, indicating a neutral trend. The MACD of -6.81 indicates Negative momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 73.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JUBLPHARMA.
Jubilant Pharmova Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹199.10B | 26.69 | ― | 0.57% | -3.79% | -20.88% | |
73 Outperform | ₹156.61B | 24.17 | ― | 0.24% | 8.14% | 5.18% | |
69 Neutral | ₹126.20B | 21.31 | ― | 0.31% | 11.41% | 19.22% | |
62 Neutral | ₹139.80B | 76.03 | ― | 0.46% | 10.09% | -19.40% | |
60 Neutral | ₹180.27B | 119.97 | ― | 0.08% | 0.34% | -14.13% | |
57 Neutral | ₹143.45B | 31.27 | ― | 1.28% | 11.42% | -1.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:JUBLPHARMA
Jubilant Pharmova Limited
877.70
-37.54
-4.10%
IN:APLLTD
Alembic Pharmaceuticals Limited
729.80
-108.31
-12.92%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
1,660.25
-204.05
-10.95%
IN:GRANULES
Granules India Limited
645.35
194.63
43.18%
IN:NATCOPHARM
NATCO Pharma Limited
1,111.60
369.07
49.70%
IN:NEULANDLAB
Neuland Laboratories Ltd.
14,050.60
2,354.89
20.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.